youtube_live
Q3 2026 earnings • in 1 day
See detailschevron_right
SNY:NASDAQ
Sanofi SA
$42.24
arrow_upward
+0.84%(+0.35) 1D
$42.40
arrow_upward
+0.38% (+0.16)todayPre-market
Closed: Oct 28, 4:00:00 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SNY...
Open
$41.83
High
$42.33
Low
$41.63
Mkt. cap
102.25B
Avg. vol.
3.35M
Volume
13.59K
Dividend
5.73%
Quarterly dividend
$0.60
Ex-dividend date
May 5, 2026
P/E ratio
23.30
52-wk high
$52.68
52-wk low
$39.07
EPS
$1.81
Beta
0.37
Shares outstanding
2.42B
No. of employees
75K
Open
$41.83
High
$42.33
Low
$41.63
Mkt. cap
102.25B
Avg. vol.
3.35M
Volume
13.59K
Dividend
5.73%
Quarterly dividend
$0.60
Ex-dividend date
May 5, 2026
P/E ratio
23.30
52-wk high
$52.68
52-wk low
$39.07
EPS
$1.81
Beta
0.37
Shares outstanding
2.42B
No. of employees
75K
News stories
From web sources and news partners
Morningstar
·
23 hours ago
What To Expect from Sanofi’s Earnings
TradingView
·
1 day ago
Sanofi SA expected to post earnings of $1.51 a share - Earnings Preview
Financial Times
·
2 days ago
Can French drugmaker Sanofi fix its pipeline?
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000.
Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About Sanofi SA
CEOPaul Hudson | Belén Garijo
Employees74.8K
Founded1973
HeadquartersParis, Île-de-France, France
SectorPharmaceutical industry
Websitesanofi.com
Analyst ratings
Based on 2 analysts giving stock ratings to SNY in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for SNY in the last 3 months.
Highest
Current $42.24
$62.00 (+46.78%)
Average
$59.50 (+40.86%)
Lowest
$57.00 (+34.94%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Steve Scala TD Cowen | Hold | Maintained | $57.00 | +34.9% | 08/31/2026 |
Unknown Analyst Berenberg Bank | Buy | Maintained | $62.00 | +46.8% | 08/24/2026 |
Seamus Fernandez Guggenheim | Hold | Maintained | - | - | 07/09/2026 |
Sarita Kapila Morgan Stanley | Hold | Maintained | $49.00 | +16% | 07/08/2026 |
Peter Verdult Exane BNP Paribas | Hold | Downgraded | $50.00 | +18.4% | 04/20/2026 |
Emily Field Barclays | Hold | Downgraded | - | - | 01/06/2026 |
Next call in 24:13:53
Fri, Oct 30, 8:30 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (EUR)
- GAAP EPS / Est. (EUR)
- / €1.51
Revenue / Est. (EUR)
- / 13.32B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in EUR | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 13.17B | 12.20B | 11.24B | 12.30B |
Cost of goods sold | 3.41B | 3.63B | 3.06B | 2.89B |
Cost of revenue | 3.41B | 3.63B | 3.06B | 2.89B |
Research and development expenses | 1.83B | 2.29B | 1.75B | 2.23B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 2.29B | 2.82B | 2.33B | 2.49B |
Operating expense | 5.97B | 6.84B | 5.94B | 6.82B |
Total operating expenses | 9.39B | 10.46B | 9.00B | 9.71B |
Operating income | 3.78B | 1.74B | 2.25B | 2.59B |
Other non operating income | - | 122.00M | -40.00M | -91.00M |
EBT including unusual items | 3.51B | -1.16B | 2.01B | 828.00M |
EBT excluding unusual items | 3.67B | 1.70B | 2.14B | 2.40B |
Income tax expense | 680.00M | -348.00M | 420.00M | 451.00M |
Effective tax rate | 19.38% | 30.13% | 20.85% | 54.47% |
Other operating expenses | 1.39B | 1.19B | 1.33B | 1.55B |
Net income | 2.80B | -801.00M | 1.61B | 343.00M |
Net profit margin | 21.28% | -6.56% | 14.35% | 2.79% |
Earnings per share | - | 1.53 | 1.88 | - |
Interest and investment income | 114.00M | 79.00M | 60.00M | 64.00M |
Interest expense | -227.00M | - | -138.00M | -153.00M |
Net interest expenses | -113.00M | 79.00M | -78.00M | -89.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 4.20B | 3.49B | 2.78B | 3.83B |
Gain or loss from assets sale | 266.00M | -79.00M | - | -9.00M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events